-
Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination J. Infect. (IF 28.2) Pub Date : 2024-03-13 Lujia Sun, Qiuhong Man, Hui Zhang, Shuai Xia, Lu Lu, Xinling Wang, Lize Xiong, Shibo Jiang
-
COVID-19 Mortality Amongst the Immunosuppresed J. Infect. (IF 28.2) Pub Date : 2024-03-11 Víctor Moreno-Torres MD PhD, María Martínez-Urbistondo MD, Jorge Calderón-Parra MD PhD, Carmen de Mendoza PhD, Vicente Soriano MD PHD
-
Clinical features-based machine learning models to separate sexually transmitted infections from other skin diagnoses J. Infect. (IF 28.2) Pub Date : 2024-03-05 Nyi Nyi Soe, Phyu Mon Latt, Zhen Yu, David Lee, Cham-Mill Kim, Daniel Tran, Jason J. Ong, Zongyuan Ge, Christopher K. Fairley, Lei Zhang
Many sexual health services are overwhelmed and cannot cater for all the individuals who present with sexually transmitted infections (STIs). Digital health software that separates STIs from non-STIs could improve the efficiency of clinical services. We developed and evaluated a machine learning model that predicts whether patients have an STI based on their clinical features. We manually extracted
-
Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: Results from a randomized controlled study J. Infect. (IF 28.2) Pub Date : 2024-03-02 Z. Al Fatly, M.G.H. Betjes, W.A. Dik, R.A.M. Fouchier, M.E.J. Reinders, A.E. de Weerd
To study the effect of mycophenolate mofetil (MMF) on various vaccination responses in kidney transplant recipients. In a randomized controlled trial (EudraCT nr.: 2014-001372-66), low immunologically risk kidney transplant recipients were randomized to TAC/MMF or TAC-monotherapy (TACmono), six months post-transplantation. One year after transplantation, in a pre-specified sub-study, recipients were
-
Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children J. Infect. (IF 28.2) Pub Date : 2024-02-29 Pengcheng Liu, Jiehao Cai, He Tian, Jingjing Li, Lijuan Lu, Menghua Xu, Xunhua Zhu, Huaqing Zhong, Ran Jia, Xiaomin Fu, Xiangshi Wang, Yanling Ge, Yanfeng Zhu, Mei Zeng, Jin Xu
-
Lymphopenia is associated with broad host response aberrations in community-acquired pneumonia J. Infect. (IF 28.2) Pub Date : 2024-02-29 Susanne E. Doeleman, Tom D.Y. Reijnders, Sebastiaan C.M. Joosten, Alex R. Schuurman, Tjitske S.R. van Engelen, Jan Verhoeff, Valentine Léopold, Xanthe Brands, Bastiaan W. Haak, Jan M. Prins, Maadrika M.N.P. Kanglie, Inge A.H. van den Berk, Daniël R. Faber, Renée A. Douma, Jaap Stoker, Anno Saris, Juan J. Garcia Vallejo, W. Joost Wiersinga, Tom van der Poll
Lymphopenia at hospital admission occurs in over one-third of patients with community-acquired pneumonia (CAP), yet its clinical relevance and pathophysiological implications remain underexplored. We evaluated outcomes and immune features of patients with lymphopenic CAP (L-CAP), a previously described immunophenotype characterized by admission lymphocyte count <0.724 × 10 cells/L. Observational study
-
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes J. Infect. (IF 28.2) Pub Date : 2024-02-29 Gail Hayward, Ly-Mee Yu, Paul Little, Oghenekome Gbinigie, Milensu Shanyinde, Victoria Harris, Jienchi Dorward, Benjamin R Saville, Nicholas Berry, Philip H Evans, Nicholas PB Thomas, Mahendra G Patel, Duncan Richards, Oliver Van Hecke, Michelle A Detry, Christina Saunders, Mark Fitzgerald, Jared Robinson, Charlotte Latimer-Bell, Julie Allen, Emma Ogburn, Jenna Grabey, Simon de Lusignan, FD Richard
The evidence for whether ivermectin impacts recovery, hospital admissions, and longer-term outcomes in COVID-19 is contested. The WHO recommends its use only in the context of clinical trials. In this multicentre, open-label, multi-arm, adaptive platform randomised controlled trial, we included participants aged ≥18 years in the community, with a positive SARS-CoV-2 test, and symptoms lasting ≤14 days
-
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study J. Infect. (IF 28.2) Pub Date : 2024-02-29 Wilhelmine Meeraus, Mark Joy, Mario Ouwens, Kathryn S Taylor, Sudhir Venkatesan, John Dennis, Trung N. Tran, Ashkan Dashtban, Xuejuan Fan, Robert Williams, Tamsin Morris, Lucy Carty, Debasish Kar, Uy Hoang, Michael Feher, Anna Forbes, Gavin Jamie, William Hinton, Kornelia Sanecka, Rachel Byford, Sneha N Anand, F.D. Richard Hobbs, David Clifton, Andrew J. Pollard, Sylvia Taylor, Simon de Lusignan
Despite being prioritized during initial COVID-19 vaccine rollout, vulnerable individuals at high risk of severe COVID-19 (hospitalization, intensive care unit admission, or death) remain underrepresented in vaccine effectiveness (VE) studies. The RAVEN cohort study (NCT05047822) assessed AZD1222 (ChAdOx1 nCov-19) two-dose primary series VE in vulnerable populations. Using the Oxford-Royal College
-
Identification of a newly emerging second-generation HIV-1 circulating recombinant form (CRF145_0755) among men who have sex with men in China J. Infect. (IF 28.2) Pub Date : 2024-02-21 Min Chen, Yanling Ma, Huichao Chen, Jie Dai, Lijuan Dong, Manhong Jia
-
Is paracetamol a missing piece of the severe acute hepatitis of unknown aetiology jigsaw? J. Infect. (IF 28.2) Pub Date : 2024-02-19 Pietro Vajro, Claudia Mandato, Björn Fischler
-
Bacteriophage therapy and current delivery strategies for orthopedic infections: A SCOPING review J. Infect. (IF 28.2) Pub Date : 2024-02-17 Jason Young, Sang W. Lee, Mohammad J. Shariyate, Alexandria Cronin, John J. Wixted, Ara Nazarian, Christopher F. Rowley, Edward K. Rodriguez
Interest in phages as adjunctive therapy to treat difficult infections has grown in the last decade. However, phage dosing and delivery for orthopedic infections have not been systematically summarized. Following PRISMA-ScR guidelines, we conducted a SCOPING review through September 1st, 2023, of MEDLINE, Embase, Web of Science Core Collection, and Cochrane Central. In total, 77 studies were included
-
People living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention J. Infect. (IF 28.2) Pub Date : 2024-02-16 Jie Zhou, Liuyan Lan, Sufang Ai, Jianyan Lin, Ningmei Liu, Yulan Xie, Ping Cui, Hao Liang, Li Ye, Jiegang Huang, Zhiman Xie
-
Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein J. Infect. (IF 28.2) Pub Date : 2024-02-16 Zhuocheng Yao, Lin Zhang, Yuange Duan, Xiaolu Tang, Jian Lu
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has substantially damaged the global economy and human health. The spike (S) protein of coronaviruses plays a pivotal role in viral entry by binding to host cell receptors. Additionally, it acts as the primary target for neutralizing antibodies in those infected and is the central focus for currently
-
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial J. Infect. (IF 28.2) Pub Date : 2024-02-16 Maya Hites, Eva Larranaga Lapique, Clément R. Massonnaud, Drifa Belhadi, Simon Jamard, François Goehringer, François Danion, Jean Reignier, Nathalie de Castro, Denis Garot, Karine Lacombe, Violaine Tolsma, Emmanuel Faure, Denis Malvy, Thérèse Staub, Johan Courjon, France Cazenave-Roblot, Anne Ma Dyrhol Riise, Paul Leturnier, Guillaume Martin-Blondel, Claire Roger, Karolina Akinosoglou, Vincent Le Moing
-
-
Antibiotics to eradicate Streptococcus pyogenes pharyngeal carriage in asymptomatic children and adults: A systematic review J. Infect. (IF 28.2) Pub Date : 2024-02-14 Te-Yu Hung, Linny K. Phuong, Anneke Grobler, Steven Y.C. Tong, Pippin Freeth, Asika Pelenda, Katherine B. Gibney, Andrew C. Steer
is a Gram-positive bacteria which causes a spectrum of diseases ranging from asymptomatic infection to life-threatening sepsis. Studies report up to 2000 times greater risk of invasive disease in close contacts of index cases within 30-days of symptom onset. Despite this, there is variability in the management of asymptomatic carriage of and those at risk of secondary cases of invasive infection. Our
-
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines J. Infect. (IF 28.2) Pub Date : 2024-02-13 Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S. Plested, Anand Parekh, Drew Gorinson, Rongman Cai, Soham Mahato, Pradhipa Ramanathan, Lidwina Carissa Aurelia, Kevin John Selva, Anthony M. Marchese, Louis Fries, Amy W. Chung, Lisa M. Dunkle
-
The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract J. Infect. (IF 28.2) Pub Date : 2024-02-10 Linlin Xie, Gengyan Luo, Zhongzhou Yang, Wei-chen Wu, Jintao Chen, Yuting Ren, Zhikun Zeng, Guangming Ye, Yunbao Pan, Wen-jing Zhao, Yao-qing Chen, Wei Hou, Yanni Sun, Deying Guo, Zifeng Yang, Jun Li, Edward C. Holmes, Yirong Li, Liangjun Chen, Mang Shi
The respiratory tract is the portal of entry for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a variety of respiratory pathogens other than SARS-CoV-2 have been associated with severe cases of COVID-19 disease, the dynamics of the upper respiratory microbiota during disease the course of disease, and how they impact disease manifestation, remain uncertain. We collected
-
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis J. Infect. (IF 28.2) Pub Date : 2024-02-06 Lorenzo Onorato, Ilaria de Luca, Caterina Monari, Nicola Coppola
The best treatment for carbapenem-resistant (CRAB) infections is still a matter of debate. To describe the outcomes of patients treated with cefiderocol for CRAB infections, and to compare the efficacy of cefiderocol versus best available therapy (BAT). We searched MEDLINE, the Cochrane Library and EMBASE to screen original reports published up to September 2023. Randomized controlled trials (RCTs)
-
A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling ‘low risk’ patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems J. Infect. (IF 28.2) Pub Date : 2024-02-06 Mamidipudi Thirumala Krishna, Rashmeet Bhogal, Bee Yean Ng, Kornelija Kildonaviciute, Yogini H. Jani, Iestyn Williams, Jonathan A.T. Sandoe, Rachel Pollard, Nicola Jones, Louise Dunsmure, Neil Powell, Chidanand Hullur, Ariyur Balaji, Catherine Moriarty, Beverley Jackson, Amena Warner, Ron Daniels, Robert West, Caroline Thomas, Siraj A. Misbah, Louise Savic
The huge burden of inaccurate penicillin allergy labels (PALs) is an important driver of antimicrobial resistance. This is magnified by insufficient allergy specialists and lack of ‘point-of-care’ tests. We investigated the feasibility of non-allergy healthcare professionals (HCPs) delivering direct oral penicillin challenges (DPCs) for penicillin allergy de-labelling. This prospective observational
-
Diagnostic accuracy of inflammatory markers in adults with suspected central nervous system infections J. Infect. (IF 28.2) Pub Date : 2024-02-05 Sabine E. Olie, Steven L. Staal, Liora ter Horst, Ingeborg E. van Zeggeren, Wing K. Man, Michael W.T. Tanck, Diederik van de Beek, Matthijs C. Brouwer
We aimed to determine diagnostic accuracy of inflammatory markers in plasma and cerebrospinal fluid (CSF) for the diagnosis of central nervous system (CNS) infections and specifically bacterial meningitis. We analyzed 12 cytokines, chemokines, and acute phase reactants in CSF and plasma of 738 patients with suspected neurological infection included in a multicenter prospective cohort. We determined
-
Corrigendum to “Tick-borne encephalitis: Acute clinical manifestations and severity in 581 cases from Germany, 2018-2020” [J Infect 86 (2023) 369-375] J. Infect. (IF 28.2) Pub Date : 2024-02-02 Teresa M. Nygren, Antonia Pilic, Merle M. Böhmer, Christiane Wagner-Wiening, Simone-Beatrice Went, Ole Wichmann, Wiebke Hellenbrand
Abstract not available
-
Pulmonary dysfunction severity may impact optimal dexamethasone dosing in patients with COVID-19 J. Infect. (IF 28.2) Pub Date : 2024-02-01 Kuo-Chuan Hung, I-Wen Chen, Cheuk-Kwan Sun
Abstract not available
-
Distinguishing community-acquired bacterial and viral meningitis: Microbes and biomarkers J. Infect. (IF 28.2) Pub Date : 2024-02-01 Lauri Ivaska, Jethro Herberg, Manish Sadarangani
Diagnostic tools to differentiate between community-acquired bacterial and viral meningitis are essential to target the potentially lifesaving antibiotic treatment to those at greatest risk and concurrently spare patients with viral meningitis from the disadvantages of antibiotics. In addition, excluding bacterial meningitis and thus decreasing antibiotic consumption would be important to help reduce
-
IgG glycosylation associates with risk of progression from latent to active tuberculosis J. Infect. (IF 28.2) Pub Date : 2024-02-01 Julie G. Burel, Wenjun Wang, Manfred Wuhrer, Martin Dedicoat, Thomas E. Fletcher, Adam F. Cunningham, Matthew K. O’Shea
Glycosylation motifs shape antibody structure, stability and antigen affinity and play an important role in antibody localization and function. Serum IgG glycosylation profiles are significantly altered in infectious diseases, including tuberculosis (TB), but have not been studied in the context of progression from latent to active TB. We performed a longitudinal study of paired bulk IgG glycosylation
-
Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance J. Infect. (IF 28.2) Pub Date : 2024-01-30 Meredith Leston, Willam Elson, Jose M. Ordóñez-Mena, Debasish Kar, Heather Whitaker, Mark Joy, Nia Roberts, F.D. Richard Hobbs, Simon de Lusignan
Effective disease surveillance, including that for COVID-19, is compromised without a standardised method for categorising the immunosuppressed as a clinical risk group. We conducted a systematic review and meta-analysis to evaluate whether excess COVID-associated mortality compared to the immunocompetent could meaningfully subdivide the immunosuppressed. Our study adhered to UK (Green Book) criteria
-
Burden of child mortality from malaria in high endemic areas: Results from the CHAMPS network using minimally invasive tissue sampling J. Infect. (IF 28.2) Pub Date : 2024-01-28 Ikechukwu U. Ogbuanu, Kephas Otieno, Rosauro Varo, Samba O. Sow, Julius Ojulong, Babatunde Duduyemi, Dickens Kowuor, Carrie Jo Cain, Emily A. Rogena, Dickens Onyango, Victor Akelo, Beth A. Tippett Barr, Feiko terKuile, Karen L. Kotloff, Milagritos D. Tapia, Adama Mamby Keita, Jane Juma, Nega Assefa, Nardos Assegid, Yenework Acham, Lola Madrid, J. Anthony G. Scott, Shams El Arifeen, Emily S. Gurley
-
DNA mismatch repair in HIV-Associated Lymphoma: Lost in Translation? J. Infect. (IF 28.2) Pub Date : 2024-01-28 Yuanhui Jiang, Suling Chen, Muye Xia, Xuwen Xu, Jie Peng, Shaohang Cai
Abstract not available
-
Less is more: Uptake of recommended vaccines in a UK travel clinic J. Infect. (IF 28.2) Pub Date : 2024-01-26 Thomas Harrison, Jacqueline Clark, Thomas C. Darton
Abstract not available
-
Longitudinal study of meningococcal carriage in adolescents and young adults in South Australia 2017-2020 J. Infect. (IF 28.2) Pub Date : 2024-01-17 Mark McMillan, Hassen Mohammed, Jana Bednarz, Lex E.X. Leong, Andrew Lawrence, Thomas R. Sullivan, Martin C.J. Maiden, Helen S. Marshall
Background This analysis investigated longitudinal changes in meningococcal carriage in adolescents in South Australia over 4 years. Methods Data from the “B Part of It” study, which included a state-wide cluster randomized controlled trial in secondary-school students (n = 34,489 in 2017 and 2018) and serial cross-sectional studies in school leavers aged 17–25 years (n = 4028 in 2019-2020). Individuals
-
Donor respiratory multidrug-resistant bacteria and lung transplantation outcomes J. Infect. (IF 28.2) Pub Date : 2024-01-17 Rayid Abdulqawi, Rana Ahmed Saleh, Reem Mahmoud Alameer, Haifa Aldakhil, Khaled Manae AlKattan, Reem Saad Almaghrabi, Sahar Althawadi, Mahmoud Hashim, Waleed Saleh, Amani Hassan Yamani, Eid Abdullah Al-Mutairy
Rationale Respiratory culture screening is mandatory for all potential lung transplant donors. There is limited evidence on the significance of donor multidrug-resistant (MDR) bacteria on transplant outcomes. Establishing the safety of allografts colonized with MDR bacteria has implications for widening an already limited donor pool. Objectives We aimed to describe the prevalence of respiratory MDR
-
SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing J. Infect. (IF 28.2) Pub Date : 2024-01-17 John M. Murray, Daniel D. Murray, Evelyne Schvoerer, Elma H. Akand
Objectives Calculations of SARS-CoV-2 transmission networks at a population level have been limited. Networks that estimate infections between individuals and whether this results in a mutation, can be a way to evaluate fitness of a mutational clone by how much it expands in number as well as determining the likelihood a transmission results in a new variant. Methods Australian Delta and Omicron SARS-CoV-2
-
Emergence of a triple reassortment avian influenza virus (A/H5N6) from wild birds J. Infect. (IF 28.2) Pub Date : 2024-01-17 Yan-kun Ke, Xin-yu Han, Si-ru Lin, Han-guang Wu, Ying-xin Li, Rong-qi Liu, Ming Liao, Wei-xin Jia
Abstract not available
-
Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies J. Infect. (IF 28.2) Pub Date : 2024-01-11 Emily F. Cornish, Lotte E. van der Meeren, Marie-Louise P. van der Hoorn, Sam Schoenmakers, Alexandre J. Vivanti, Alexandra Benachi, Melissa Whitten, Stephanie Hignett, Thomas McDonnell, David J. Williams
Abstract not available
-
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency J. Infect. (IF 28.2) Pub Date : 2024-01-06 Haoran Zhang, Kangping Zhou, Fei Peng, Zhao Gao,, Guowei Song, Bing Hu, Sophia Chun, Junfeng Xiao, Mengfei Qian, Jin Wu, Kai Pan, Fan Gao, Meng Guo, Cheng Peng, Gang Zou, Jim Zhen Wu, Kun Cai, Yan Li
Abstract not available
-
Hepatitis B virus (HBV) screening, linkage and retention-in-care in inclusion health populations: Evaluation of an outreach screening programme in London J. Infect. (IF 28.2) Pub Date : 2023-12-29 Emily Martyn, Sive O’Regan, Philippa Harris, Mark Leonard, Martha Veitch, Binta Sultan, Philippa C. Matthews, Indrajit Ghosh, Alistair Story, Julian Surey
Objectives We evaluate a hepatitis B virus (HBV) screening programme, delivered by a specialist pan-London multidisciplinary outreach team, to understand population characteristics and care cascade among people who experience extreme social exclusion (Inclusion Health (IH) groups). Methods Point-of-care HBV screening was performed in temporary accommodation for people experiencing homelessness (PEH)
-
Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry J. Infect. (IF 28.2) Pub Date : 2023-12-22 Damien Caillet Portillo, Xavier Puéchal, Maëva Masson, Marie Kostine, Alexia Michaut, André Ramon, Daniel Wendling, Nathalie Costedoat-Chalumeau, Pascal Richette, Hubert Marotte, Justine Vix-Portet, Jean-Jacques Dubost, Sébastien Ottaviani, Gaël Mouterde, Anne Grasland, Aline Frazier, Vincent Germain, Fabienne Coury, Anne Tournadre, Martin Soubrier, Arnaud Constantin
Objectives Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease-modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease. Methods We initiated a registry including patients with disease-modifying
-
Economic burden attributable to healthcare-associated infections at western China hospitals: 6 Year, prospective cohort study J. Infect. (IF 28.2) Pub Date : 2023-12-21 Yu Lv, Xiaobo Huang, Jiayu Wu, Xueqin Xiao, Chunhua Ma, Xiaoyun Jiang, Ping Zhou, Linlin Liu, Yiguo Jiang, Anna Zou, Hui Niu, Juhua Sun, Li Hou, Xiaomeng Wang, Yulin Dai, Shuling Peng, Xiaorong Deng, Hong Xia, Yao Guo, Defen Wang, Qian Xiang
Objectives Healthcare-associated infections (HAIs) represent a major threat to patient safety and are associated with significant economic burden. Calculating the costs attributable to HAIs is challenging given the various sources of bias. Although HAIs as a reasonably preventable medical harm should have been closely linked to medical insurance incentives, there was little linkage between HAIs and
-
Beethoven’s deafness more likely linked to viral infection than lead poisoning J. Infect. (IF 28.2) Pub Date : 2023-12-21 Piotr Rzymski, Dorota Zarębska-Michaluk, Robert Flisiak
Abstract not available
-
Characterization of a new HIV-1 second-generation circulating recombinant form (CRF170_0107) among men who have sex with men in Yunnan, China J. Infect. (IF 28.2) Pub Date : 2023-12-20 Yi Li, Wei Chang, Jun Liang, Yang Liu, Li Li, Li Liu, Jing-Ying Wang, Rui-Lin Feng, Bin Liao, Yue Feng
Abstract not available
-
Development and validation of the Baseline Recurrence Risk in Cellulitis (BRRISC) score J. Infect. (IF 28.2) Pub Date : 2023-12-20 Elizabeth L.A. Cross, T. Phuong Quan, Gail N. Hayward, A. Sarah Walker, Martin J. Llewelyn
Objectives Cellulitis is often treated with antibiotics for longer than recommended by guidelines. Prolonged therapy may reduce recurrence in certain patients, but it is not known which patients are at greatest risk. Our objective was to develop and temporally validate a risk prediction score to identify patients attending hospital with cellulitis at highest risk of recurrence. Methods We included
-
The association between phylogenetic lineage and the subclinical phenotype of pulmonary tuberculosis: A retrospective 2-cohort study J. Infect. (IF 28.2) Pub Date : 2023-12-15 Richard Long, Matthew Croxen, Robyn Lee, Alexander Doroshenko, Angela Lau, Leyla Asadi, Courtney Heffernan, Catherine Paulsen, Mary Lou Egedahl, Colin Lloyd, Vincent Li, Gregory Tyrrell
Background Subclinical pulmonary tuberculosis (PTB) is an asymptomatic disease state between established TB infection and symptomatic (clinical) TB disease. It is present in 20-25% of PTB patients in high-income countries. Mycobacterium tuberculosis complex (MTBC) genetic heterogeneity, and differential host immunological responses, have been implicated in its pathogenesis. Methods To determine the
-
Virus-containing migrasomes enable poxviruses to evade tecovirimat/ST-246 treatment J. Infect. (IF 28.2) Pub Date : 2023-12-15 Wenbo Zhao, Xichi Tang, Leiliang Zhang
Abstract not available
-
Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis J. Infect. (IF 28.2) Pub Date : 2023-12-13 Cesar Fernandez-de-las-Peñas, Kin Israel Notarte, Raymart Macasaet, Jacqueline Veronica Velasco, Jesus Alfonso Catahay, Abbygail Therese Ver, William Chung, Juan A. Valera-Calero, Marcos Navarro-Santana
Objective This meta-analysis investigated the prevalence of post-COVID symptoms two-years after SARS-CoV-2 infection. Methods Electronic literature searches on PubMed, MEDLINE, CINAHL, EMBASE, Web of Science databases, and on medRxiv/bioRxiv preprint servers were conducted up to October 1, 2023. Studies reporting data on post-COVID symptoms at two-years after infection were included. Methodological
-
Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection J. Infect. (IF 28.2) Pub Date : 2023-12-13 Kexin Zong, Ping Yuan, Ruifang Wang, Qin Luo, Yanqing Yang, Xiaohong Zhang, Qinqin Song, Haijun Du, Chen Gao, Juan Song, Weihua Zhan, Mengjie Zhang, Yanhai Wang, Qunying Lin, Hailan Yao, Baosong Xie, Jun Han
The symptoms of children infected with SARS-CoV-2 are mainly asymptomatic, mild, moderate, and a few severe cases. To understand the immune response characteristics of children infected with SARS-COV-2 who do not develop severe cases, 82 children infected with the SARS-CoV-2 delta strain were recruited in this study. Our results showed that high levels of IgG, IgM, and neutralization antibodies appeared
-
Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC) after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker cohort J. Infect. (IF 28.2) Pub Date : 2023-12-07 Carol Strahm, Christian R. Kahlert, Sabine Güsewell, Danielle Vuichard-Gysin, Reto Stocker, Stefan P. Kuster, Philipp Kohler
Abstract not available
-
Reconsidering the etiology of Beethoven's deafness: A cautionary perspective on chronic HBV infection J. Infect. (IF 28.2) Pub Date : 2023-12-06 Zichen Li, Leiliang Zhang
Abstract not available
-
A novel quantitative urine LAM antigen strip for point-of-care tuberculosis diagnosis in non-HIV adults J. Infect. (IF 28.2) Pub Date : 2023-11-29 Zhen Huang, Huan Huang, Jing Hu, Lu Xia, Xuhui Liu, Rong Qu, Xiaolin Huang, Yang Yang, Kang Wu, Ruiqing Ma, Jinchuan Xu, Zhenyan Chen, Yuhao Wu, Juan Yang, Yong Fang, Jianfeng Zeng, Weihua Lai, Guodong Sui, Wei Sha, Yonghua Xiong, Xiao-Yong Fan
Abstract not available
-
Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: A prospective multicentre cohort (NO-BACT) J. Infect. (IF 28.2) Pub Date : 2023-11-28 José Antonio Girón-Ortega, Raquel Fernández-Guerrero, Montserrat Montes de Oca Arjona, Fátima Galán-Sanchez, Galadriel Pellejero Sagastizábal, Elena Morte Romea, Marina de Cueto, Margarita Beltrán Garcia, Zaira Palacios-Baena, Silvia Jiménez Jorge, Jesús Rodríguez-Baño, Pilar Retamar-Gentil
Objectives To evaluate the appropriateness of antimicrobial treatment and the risk factors for mortality in patients with negative blood cultures (BC), in order to evaluate whether this population would be a suitable target for antimicrobial stewardship (AMS) interventions. Methods A multicentre prospective cohort study of patients with negative BC in three Spanish hospitals between October 2018 and
-
-
A new era of Open Access for the Journal of Infection J. Infect. (IF 28.2) Pub Date : 2023-11-24 Robert C. Read, David G. Partridge
Abstract not available
-
Demystifying the global outbreak of severe acute hepatitis of unknown aetiology in children: A systematic review and meta-analysis J. Infect. (IF 28.2) Pub Date : 2023-11-24 Julie Phan, Guy D. Eslick, Elizabeth J. Elliott
Background The sudden outbreak of severe acute hepatitis of unknown aetiology (SAHUA) in the first half of 2022 affected more than 1010 children in 35 countries worldwide. Dire clinical outcomes, such as acute liver failure necessitating transplantation, neurological symptoms, long-term sequelae, and death, highlight the need to determine the pathogenesis of this condition. Hypotheses on the aetiology
-
Low-grade endotoxemia is associated with cardiovascular events in community-acquired pneumonia J. Infect. (IF 28.2) Pub Date : 2023-11-23 Roberto Cangemi, Roberto Carnevale, Cristina Nocella, Camilla Calvieri, Simona Bartimoccia, Giacomo Frati, Pasquale Pignatelli, Vittorio Picchio, Francesco Violi
Objectives Community-acquired pneumonia (CAP) is associated with low-grade endotoxemia but its relationship with cardiovascular events (CVE) has not been investigated. Methods We evaluated the incidence of CVE including myocardial infarction, stroke, and cardiovascular death in 523 adult patients hospitalized for CAP. Serum lipopolysaccharide (LPS) and zonulin, a marker of gut permeability, were analyzed
-
Increasing incidence of community-acquired adult group A streptococcal meningitis in the Netherlands J. Infect. (IF 28.2) Pub Date : 2023-11-22 Evelien H.G.M. Drost, Nora Chekrouni, Thijs M. van Soest, Kim Schipper, Nina M. van Sorge, Matthijs C. Brouwer, Diederik van de Beek
Abstract not available
-
Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients J. Infect. (IF 28.2) Pub Date : 2023-11-21 Santiago Grau, José Miguel Vela, Alba Gurt, Jaime Barceló-Vidal, Fabiola Ojeda, Iago López, Laura Gómez-García, María Isabel Loza, Elena Martín-García, Rafael Maldonado, Jordi Monfort
Abstract not available
-
A decade of Campylobacter and Campylobacter bacteraemias in a district general hospital and the surrounding London and South East region, England J. Infect. (IF 28.2) Pub Date : 2023-11-21 Alice Graham, Lois Hawkins, Sooria Balasegaram, Subha Narasimhan, John Wain, John Clarke, Rohini Manuel
Background Campylobacter bacteraemia is a rare complication of the most common bacterial gastrointestinal infection but is associated with significant morbidity and mortality. There is limited data describing current trends in surveillance and antimicrobial resistance for the Campylobacter strains involved. At the Epsom and St Helier’s University Hospital (ESTH), we noted a marked increase in Campylobacter
-
Machine learning-based colistin resistance marker screening and phenotype prediction in Escherichia coli from whole genome sequencing data J. Infect. (IF 28.2) Pub Date : 2023-11-20 Yingxin Tian, Di Zhang, Fangyuan Chen, Guanhua Rao, Ying Zhang
Abstract not available
-
Identification of a novel HIV-1 circulating recombinant form CRF157_A6C in Primorsky Territory, Russia J. Infect. (IF 28.2) Pub Date : 2023-11-20 Maksim R. Halikov, Vasily E. Ekushov, Alexei V. Totmenin, Natalya M. Gashnikova, Mariya E. Antonets, Tatyana V. Tregubchak, Lidiia P. Skliar, Natalia P. Solovyova, Irina S. Gorelova, Svetlana N. Beniova
Abstract not available
-
How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: An 18-month longitudinal study J. Infect. (IF 28.2) Pub Date : 2023-11-20 A.N. Diep, J. Schyns, C. Gourzones, E. Goffin, I. Papadopoulos, S. Moges, F. Minner, O. Ek, G. Bonhomme, M. Paridans, N. Gillain, E. Husson, M. Garigliany, G. Darcis, C. Saegerman, D. Desmecht, M. Guillaume, Donneau A.F., F. Bureau, L. Gillet
Abstract not available
-
Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation J. Infect. (IF 28.2) Pub Date : 2023-11-15 Nathan J. Brendish, Cai Davis, Mary E. Chapman, Florina Borca, Daniel Waddington, Christopher Hill, Nicola White, Tristan W. Clark
Objectives FebriDx is a CE-marked, FDA-approved point-of-care test that detects the antiviral host response protein Myxovirus Resistance Protein A (MxA), in addition to C-reactive protein, using finger-prick blood. FebriDx MxA detection had a high negative predictive value for COVID-19 in symptomatic adults presenting to hospital in the first waves of the pandemic and was used subsequently as a ‘rule